Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03376581 · ClinicalTrials.gov registry record · Early Phase 1
The Utility of Platelet Rich Plasma in Hair Loss
A Early Phase 1 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT03376581: Completed Early Phase 1 study, sponsored by University of California, Irvine.
NCT03376581 is a Early Phase 1 study that has completed, run by University of California, Irvine. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03376581, a Early Phase 1 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation. The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.
Interventions
- PROCEDURE Platelet rich plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2019-02-20 |
| Phase | Early Phase 1 |
What the finished NCT03376581 record still lists
NCT03376581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which Platelet rich plasma is the first listed.
NCT03376581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03376581 about?
NCT03376581 is a clinical study titled "The Utility of Platelet Rich Plasma in Hair Loss". Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation. The purpose of this research is to investigate the potential of PRP injection for treatmen...
What is the current status of trial NCT03376581?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-11-28. Estimated completion is 2019-02-20.
What interventions are being tested in trial NCT03376581?
The interventions under investigation include: Platelet rich plasma (PROCEDURE).
Who is sponsoring clinical trial NCT03376581?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03376581's enrollment target sits among peer trials
30 807th of 2000 higher than 1,075 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI